Supplemental Figure 2 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
crossref（2023）
摘要
Overall response to pembrolizumab monotherapy (n=31, left) and combination therapy (n=34*, right).
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要